Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease-Reference-Cited by-同舟云学术

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

Published:2024-08-21 Issue:1 Volume:16 Page:
ISSN:1949-0976
Container-title:Gut Microbes
language:en
Short-container-title:Gut Microbes

Author:

Prins Femke M.¹²^ORCID,Hidding Iwan J.¹^ORCID,Klaassen Marjolein A.Y.¹,Collij Valerie¹^ORCID,Schultheiss Johannes P.D.³^ORCID,Uniken Venema Werna T.C.¹^ORCID,Bangma Amber¹^ORCID,Aardema Jurne B.¹,Jansen Bernadien H.¹,Mares Wout G.N.⁴,Witteman Ben J.M.⁴,Festen Eleonora A.M.¹^ORCID,Dijkstra Gerard¹^ORCID,Visschedijk Marijn C.¹^ORCID,Fidder Herma H.³,Vich Vila Arnau⁵⁶^ORCID,Oldenburg Bas³,Gacesa Ranko¹⁷^ORCID,Weersma Rinse K.¹⁷^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

2. Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

3. Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands

4. Gastroenterology and Hepatology Department, Hospital Gelderse Vallei, Ede, The Netherlands

5. Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium

6. Center for Microbiology, VIB, Leuven, Belgium

7. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Funder

Johnson & Johnson

Takeda Pharmaceuticals

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19490976.2024.2391505

Reference23 articles.

1. The Burden of Inflammatory Bowel Disease in Europe in 2020

2. Gut microbiota in the pathogenesis of inflammatory bowel disease

3. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

4. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

5. Surgery in the age of biologics